This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.
Study Type
OBSERVATIONAL
Enrollment
600
According to the product label
According to the product label
Mebix. Inc.
Minato-ku, Tokyo, Japan
RECRUITINGFukuoka University Hospital
Fukuoka, Japan
RECRUITINGChange in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib.
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieved Physician's Global Assessment (PGA) of 0/1 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieved Absolute Psoriasis Area and Severity Index (aPASI) of ≤2 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0 /1 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation)
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib or apremilast
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0/1 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation) from baseline to follow-up
First line of the email MUST contain NCT # and Site #.
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants treated with deucravacitinib with a change in Physician's Global Assessment (PGA) from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants treated with deucravacitinib with a change in Dermatology Life Quality Index (DLQI) from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants achieving a Dermatology Life Quality Index (DLQI) score of ≤5 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieve a Psoriasis Area Severity Index (PASI) response of 75 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieve a Psoriasis Area Severity Index (PASI) response of 90 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieve an absolute Psoriasis Area Severity Index (aPASI) score ≤5 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieve an absolute Psoriasis Area Severity Index (aPASI) score ≤3 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieve a National Psoriasis Foundation (NPF) Acceptable Body Surface Area response from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieve an absolute scalp-specific Physician's Global Assessment (ss-PGA) of 0/1 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieve an absolute Physician's Global Assessment-Fingernail (PGA-F) of 0/1 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years
Number of participants who achieve an absolute Palmoplantar Physician's Global Assessment (pp-PGA) of 0/1 from baseline to follow-up
Time frame: 1 month, 3 months, 6 months and every 6 months up to 5 years